Carisma Therapeutics, Inc. (CARM)
OTCMKTS · Delayed Price · Currency is USD
0.0428
+0.0010 (2.34%)
At close: Feb 27, 2026
Carisma Therapeutics Revenue
Carisma Therapeutics had revenue of $45.25M in the quarter ending September 30, 2025, with 1,236.78% growth. This brings the company's revenue in the last twelve months to $52.63M, up 159.68% year-over-year. In the year 2024, Carisma Therapeutics had annual revenue of $19.63M with 31.59% growth.
Revenue (ttm)
52.63M
Revenue Growth
+159.68%
P/S Ratio
0.03
Revenue / Employee
1.14M
Employees
46
Market Cap
1.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.63M | 4.71M | 31.59% |
| Dec 31, 2023 | 14.92M | 5.09M | 51.71% |
| Dec 31, 2022 | 9.83M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LakeShore Biopharma | 84.75M |
| Evofem Biosciences | 17.73M |
| Clearside Biomedical | 3.33M |
| Vaccinex | 601.00K |
| Halberd | 6.94K |
Carisma Therapeutics News
- 3 months ago - Carisma Announces Delisting from Nasdaq and SEC Deregistration - PRNewsWire
- 11 months ago - Carisma Therapeutics Provides Corporate Updates - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PRNewsWire
- 1 year ago - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PRNewsWire